Ipsen reports extended Dysport-for-CP data

The principal investigator (PI) for a randomized controlled trial of Basking Ridge, NJ-based Ipsen Biopharmaceutical’s Dysport on September 22 reported extension study data on the botulinum toxin type A (ABO) for pediatric patients with cerebral palsy (CP) at the American Academy of Cerebral Palsy and Developmental Medicine annual meeting in Hollywood, FL.

The principal investigator (PI) for a randomized controlled trial of Basking Ridge, NJ-based Ipsen Biopharmaceutical’s Dysport on September 22 reported extension study data on the botulinum toxin type A (ABO) for pediatric patients with cerebral palsy (CP) at the American Academy of Cerebral Palsy and Developmental Medicine annual meeting in Hollywood, FL.

More here:
Ipsen reports extended Dysport-for-CP data